Streetbeat News

TEM

Tempus AI Inc.

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

42.00

Mkt cap

6.5B

Volume

High

43.94

P/E Ratio

-7.95

52-wk high

79.49

Low

40.66

Div yield

N/A

52-wk low

22.89

Tempus AI is enhancing its growth and competitive edge in AI health tech through strategic acquisitions and partnerships, including Ambry Genetics and a joint venture with SoftBank. The company's Data & Services division shows promising revenue growth and gross margins, positioning it for future profitability.

Portfolio Pulse from

December 08, 2024 | 12:15 pm

Tempus AI has acquired Ambry Genetics, which will expand its testing portfolio and redefine precision medicine. This acquisition is expected to enhance Tempus AI's capabilities in the field of genetic testing and precision medicine.

Portfolio Pulse from

November 25, 2024 | 7:45 pm

Tempus AI, Inc., a company leveraging AI for precision medicine, has shown strong growth since its June 2024 listing. It presents a buying opportunity due to its vast data library, advanced AI algorithms, and partnerships with Merck and BioNTech. Despite concerns over profitability and cash burn, its revenue growth and strategic acquisitions make it a compelling long-term investment.

Portfolio Pulse from

November 12, 2024 | 10:15 pm

Tempus AI, Inc. (NASDAQ:TEM) held its Q3 2024 earnings call on November 4, 2024. Key participants included CEO Eric Lefkofsky and CFO Jim Rogers, with analysts from major financial institutions attending.

Portfolio Pulse from

November 09, 2024 | 10:30 am

Tempus reported strong third-quarter earnings and revenues that exceeded estimates, driven by robust segmental performance. Despite this, the company's stock declined due to ongoing operational losses.

Portfolio Pulse from

November 05, 2024 | 4:45 pm

Avacta Therapeutics has initiated a collaboration with Tempus AI to enhance its pre|CISION® platform by identifying full addressable patient populations for its clinical programs. Tempus will provide analytical support and computational biology expertise.

Portfolio Pulse from Benzinga Newsdesk

October 21, 2024 | 11:05 am

Loop Capital has maintained a Buy rating on Tempus AI and raised its price target from $48 to $57, indicating confidence in the company's future performance.

Portfolio Pulse from Benzinga Newsdesk

October 15, 2024 | 12:03 pm

B of A Securities has downgraded Tempus AI from Buy to Neutral, while raising its price target from $45 to $60.

Portfolio Pulse from Benzinga Newsdesk

October 02, 2024 | 11:23 am

Tempus AI, Inc. has expanded its collaboration with Takeda to enhance oncology research using Tempus' multimodal datasets and biological modeling. This partnership aims to advance Takeda's cancer therapeutics pipeline.

Portfolio Pulse from Benzinga Newsdesk

September 26, 2024 | 12:35 pm

Cathie Wood's Ark Invest continues to sell shares of Robinhood and Palantir, despite favorable market conditions for Robinhood following a Federal Reserve rate cut. Ark's trades align with its recent pattern of reducing holdings in these companies.

Portfolio Pulse from Benzinga Neuro

September 19, 2024 | 2:28 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.